PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/550.661 Filing Date TRANSMITTAL September 26, 2005 First Named Inventor FORM et jebig Brown Art Unit Unknown Examiner Name Unknown (to be used for all correspondence after initial filing) Attorney Docket Number 101025-1P US Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a Proprietary Information Provisional Application After Final Power of Attorney, Revocation Status Letter Change of Correspondence Address Affidavits/declaration(s) Other Enclosure(s) (please Identify Terminal Disclaimer below): Extension of Time Request Request for Refund **Express Abandonment Request** CD. Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Signature Printed name Jianzhong Shen Date Reg. No. 48,076 January 2, 2006 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Date Liz Ashton

Typed or printed name This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.: 10/550,661

Confirmation No.: Unknown

Applicant: Brown et al.

PCT Appl. No.: PCT/SE2004/000504

National Phase Fld (371): September 26, 2005

PCT Filed: April 1, 2004

Docket No.: 101025-1P US

TC/A.U.: Unknown

Customer No.:22466

Examiner: Unknown

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit herewith a list of patents and publications for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

Applicants also wish to make the Examiner aware of co-pending applications:

10/477851, a PCT national phase filed on May 16, 2002;

10/477854, a PCT national phase filed on May 16, 2002;

10/477641, a PCT national phase filed on May 16, 2002;

10/477821, a PCT national phase filed on May 16, 2002;

10/240114, a PCT national phase filed on March 30, 2001;

10/240038, a PCT national phase filed on March 30, 2001;

10/222990, filed on August 19, 2002;

10/541522, a PCT national phase filed on January 13, 2004;

10/541656, a PCT national phase filed on January 13, 2004; and

10/541664, a PCT national phase filed on January 13, 2004.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

This Information Disclosure Statement is being filed before the mailing date of a first office action on the merits and therefore, pursuant to 37 C.F.R. § 1.97(b), no fee is required pursuant to 37 C.F.R. § 1.17(p).

Respectfully submitted,

Name: Jianzhong Shen Dated: January 2, 2006

Reg. No. 48,076

Phone No. 302-886-8854

Global Intellectual Property, Patents,

AstraZeneca,

1800 Concord Pike,

Wilmington, DE-19850-5437

Enclosures:

Form PTO/SB/08A (3 pgs)

Form PTO/SB/08B (1 pg)

References (19)

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

r the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

JAN 0 8 7006

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4

Complete if Known		
Application Number	10/550,661	
Filing Date	September 26, 2005	
First Named Inventor	Brown	
Art Unit	Unknown	
Examiner Name	Unknown	
Attorney Docket Number	101025-1P US	

		_	U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
_	-	Number-Kind Code ^{2 (f known)} US- 2,898,339	08-04-1959	Wheeler et al.	
		^{US-} 4,581,171	04-08-1986	Kennis et al.	
		^{US-} 4,816,586	03-28-1989	Portoghese	
		^{US-} 4,939,137	07-03-1990	Russell et al.	
		^{US-} 5,140,029	08-18-1992	Kennis et al.	
		^{US-} 5,574,159	11-12-1996	Chang et al.	
		^{US-} 5,683,998	11-04-1997	Shibayama et al.	
		^{US-} 6,187,792	02-13-2001	Delorme et al.	
		^{US-} 6,455,545	09-24-2002	Delorme et al.	
		^{US-} 6,552,036	04-22-2003	Boyd et al.	
		^{US-} 6,556,387	04-29-2003	Misso et al.	
		^{US-} 6,756,387	06-29-2004	Brown et al.	
		US-			
		US-	1		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Г
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	
		WO 93/15062	08-05-1993	The Wellcome Foundation		
		WO 97/23466	07-03-1997	Astra Aktiebolag		
		WO 98/28275	07-02-1998	Astra Pharma Inc,		
		WO 99/33806	07-08-1999	Ortho-McNeil Pharmaceutic		
•		WO 01/74804	10-11-2001	AstraZeneca AB		Ľ
		WO 01/74806	10-11-2001	AstraZeneca AB		Γ

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Interest of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it contains a valid OMB control number.

e Paperwork Reduction Act of 1995, no persons are required to resp

stitute for form 1449/PTO

Sheet 2

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	10/550,661				
Filing Date	September 26, 2005				
First Named Inventor	Brown				
Art Unit	Unknown				
Examiner Name	Unknown				
Attorney Docket Number	101025-1P US				

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	<u> </u>	US-			
		US-	_		
		US-			
•		US-			
		US-			
		US-			
		US-			
•	<u> </u>	US-			
		US-			

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T6
		WO 02/094782	11-28-2002	AstraZeneca AB		
		WO 02/094783	11-28-2002	AstraZeneca AB		
		WO 02/094784	11-28-2002	AstraZeneca AB		
		WO 02/094785	11-28-2002	AstraZeneca AB		
		WO 02/094786	11-28-2002	AstraZeneca AB		
		WO 02/094812	11-28-2002	AstraZeneca AB		

Examiner	 Date	
Signature	Considered	
o.ga.a.		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

3 of 4

Complete if Known					
Application Number	10/550,661				
Filing Date	September 26, 2005				
First Named Inventor	Brown				
Art Unit	Unknown				
Examiner Name	Unknown	•			
Attorney Docket Number	101025 1D LIC				

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (if known)}			r igures Appeal
	,	US-			
		US-			
	· · · · ·	US-			
		US-	1		
		US-	T		
		US-			
		US-			-
		US-			
		US-			
		US-			
	 	US-			

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Т
		WO 03/029215	04-10-2003	AstraZeneca AB		
						L
						L
				<u> </u>		┡
						L

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent And Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent

OSAStitute for form 1449/PTO	Complete if Known		
il	Application Number	10/550,661	
INFORMATION DISCLOSURE	Filing Date	September 26, 2005	
STATEMENT BY APPLICANT	First Named Inventor	Brown	
(Use as many sheets as necessary)	Art Unit	Unknown	
(USB as many sheets as necessary)	Examiner Name	Unknown	
Sheet 4 of 4	Attorney Docket Number	101025-1P US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
		BARBER, A. et al., "Antinociceptive effects of the 5-HT2 Antagonist Ritanserin in Rats: Evidence in the Spinal Cord," Neuroscience Letters, 1989, Vol. 99, pgs 234-238	
		BILSKY, E. et al., "SNC 80, A Selective, Nonpeptidic and Systematically Active Opioid Delta Agonist," J. Pharmacology Experimental Ther., 1995, Vol. 273, pgs. 359-366	
		GREENE T., "Protective Groups in Organic Synthesis," Wiley & Sons, 1982, pgs. 218, 220, 232, 233, 251	
		TAKEMORI, A.E. et al., "Selective Natrexone-Derived Opioid Receptor Antagonists," Annu. Rev. Pharmacol. Toxicol., 1992, Vol. 32, pgs. 239-269	
		WEI, Z. et al., "N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide A Novel and its Analogues," J. Med. Chem., 2000, Vol. 43, pgs. 3895-3905	
		ZHANG, X. et al., "Probes for Narcotic Receptor Mediated Phenomena. 26. 1-3 Synthesis Opioid Receptor Ligands, J. Med. Chem., 1999, Vol. 42, pgs. 5455-5463	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.